Human genomics is now, more than ever, poised to ask, and answer, challenging questions pertaining to the relationship between the inherent variability observed in populations and human diseases. Whether it is susceptibility or resistance, sensitivity to drugs or, indeed, differences in the host response to infection, it is evident that common genetic variants will emerge as a key component of a comprehensive understanding of many infectious diseases [1] . Traditionally, classical medical genetics has elucidated instances in which single, highly penetrant gene mutations have resulted in major defects in host defenses against infection. These rare instances of defects that result in immunodeficiency, which often segregate in families, have underscored key components of host defenses and have led to important insights into the complex mechanisms required for protection against pathogens (e.g., chronic granulomatous disease and Wiskott-Aldrich syndrome). Indeed, even diseases considered to be affected by single genes will most likely be affected by genetic modification [2] .
Two major trends during the last 5 years have dramatically increased the opportunities for investigating the contribution of common genetic variants to complex diseases. In fact, some now argue that all diseases are complex and have a genetic contribution to susceptibility or outcome. Already, a number of genes have been identified that confer susceptibility to malaria or HIV infection [3, 4] . Major improvements in the technological platforms for genotyping the most common variants in the genome-the single-nucleotide polymorphism (SNP) together with bioinformatic tools for manipulating large sets of data on genetic information-now enable researchers to look comprehensively across genes or, for that matter, the entire genome. The International HapMap Project has generated a dense map of 14 million common SNPs in 3 distinct populations (European, West African [the Yoruba], and East Asian) [5] . Still, it is estimated that there are at least 10 million common SNPs (i.e., a minor allele frequency of 15% in at least 1 population) in the human genome, with an average spacing of !500 bp [6] . By definition, a complex disease is not explained by variation in 1 or 2 genes but instead by many genes, each of which contributes in a small way. In addition, the role played by the environment is critical, particularly because of the interaction between the host and a pathogen. In this context, it has emerged that the shift toward looking at common variants also means that the effect of any variant is expected to be small. The sample size required to detect even moderate genetic effects is large (e.g., hundreds or thousands) and, in this respect, classical genetic linkage studies are not effective. This is partly because even large studies are underpowered to detect any deviation from expected allele sharing proportions in affected families for low-penetrance alleles [7] . To discover and validate genetic determinants with a relative risk of !2, a succession of population-based studies are needed to discover and validate genetic markers for the outcome of interest. Genetic association analyses aim to establish whether an observable phenotype may be attributed to any given genetic marker by measuring the frequency of that marker in a population of case patients and control subjects and applying appropriate statistical tests of significance of intergroup difference.
Genetic associations may be tested either directly or indirectly. In the direct approach, SNPs are chosen on the basis of a priori knowledge of biological function gleaned through functional observations or on the basis of candidate genes. In the past, the choice of variant(s) was driven by prior insights, but the exponential increase in annotation of common variants has generated a catalog of variants, of which we know nothing of the function for the vast majority. In place of the candidate functional variant has emerged the indirect approach, which uses the ancestral relationship between SNPs to monitor SNPs in a region and determine if 1 or more is associated with an outcome. Linkage disequilibrium (LD), the nonrandom association between genetic markers on the same chromosome, can be exploited to detect an association on the premise that a genotyped marker may be linked to the causal variant. This kind of "surrogacy" enables one to find the region or part of a gene without knowing the exact function of either the gene or the causal variant.
The vast majority of SNPs have no functional consequence, yet investigators have naturally biased their SNP selection to enrich for SNPs that have a high prior probability of being functional. Nonetheless, this approach misses the point that by careful selection of markers it is possible to gain a much wider effective field of vision. It now makes sense that better coverage of a candidate region increases the chance of success, as opposed to searching for the proverbial needle in a haystack.
The indirect testing approach is predicated on the fact that the human genome is broadly organized into units, which have been described as "linear blocks" and "interdigitating bins" [8, 9] . The majority of SNPs are in LD with other SNPs. Thus, an association found between a trait and a SNP does not necessarily indicate causality, because the genotyped SNP could be a marker for the causative variant. In practice, knowledge of the patterns of LD in a population allows for the selection of a minimally redundant set of "tagSNPs" through which it is possible to infer the remaining variation of the haplotype [10, 11] . It is important to be aware that there can be erosion of intermarker linkage, even over short distances in unrelated case patients and control subjects [12] . Moreover, the disintegration of LD can vary by population, which means that distinct markers might have to be chosen for different populations; this has key implications for tag selection [13] . It is of the utmost importance that the LD map used be representative of the study population. To date, efforts to verify the transferability of HapMap data to other populations have been encouraging [14, 15] .
In the study by Do et al. [16] in this issue of the Journal, the authors used a comprehensive indirect strategy and surveyed 1100 SNPs in an AIDS cohort. The detailed annotation of the common genetic variant permitted the authors to look across this region for signal. Indeed, they have made a preliminary observation that a SNP in the interleukin-1 receptor antagonist gene (IL1RN) could be associated with progression of AIDS. Although their study is not definitive with respect to this association, partly because of the sample size, it does serve as an excellent example of the value of using a comprehensive genetical approach.
By choosing extremes of phenotype, Do et al. enhanced the opportunity to detect genetic variants that contribute to a complex disease and its outcome, namely progression. Furthermore, the study design was an advantage, because case patients and control subjects were recruited from the same parent population, and all case patients were infected with HIV-1 subtype B. In this regard, there was little likelihood of an effect of population stratification or confounding by infection with different HIV subtypes. Do et al. wisely chose to resequence the genes of interest in an initial polymorphism discovery phase; this was sufficiently powered to detect 199% of the SNPs with a minor allele frequency of 1% or greater [17] . This strategy enabled them to avoid the caveat of the transferability of population-specific haplotype block structure, as discussed above. In Do et al.'s study, the IL1RN haploblock 0 was more often found in slow progressors than in rapid progressors, although the analysis compared the groups to HIVnegative control subjects. In the future, it will be critical to compare groups within a cohort (such as slow and fast progressors) to identify markers of outcome that could be useful in clinical decision making.
HIV-1 infection has been aggressively pursued by geneticists, and several genes have common variants that have been confirmed as important markers for HIV-1 infection and also progression. For instance, CCR5-D32 and CCR2-64I are associated with later onset of AIDS or death [18] . However, much of the variation has yet to be explained. It is now possible to consider conducting whole-genome scans in well-designed cohort studies in which there are enough subjects for replication of results and analysis of outcomes, such as progression or specific complications of HIV-1 infection (e.g., Pneumocystis carinii pneumonia). Given the resources needed to do this well, careful planning is required to ensure not only that true positives can be found but also that regions that should no longer be pursued can be ruled out [19] .
If we are to use the resources at hand and map complex diseases, our success will depend on more than the ability to analyze large sets of genotypes and drill down toward the causal variants. We now need to focus on designing studies in which we pay close attention to the size of the study and the phenotypes under analysis. Confirmation of results in large independent cohorts must become the criterion standard. Collaborations involving genomicists, clinicians, and statisticians should become commonplace and should involve multicenter consortia to solve current problems of power and design.
